KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Acquisitions (2023 - 2025)

Regeneron Pharmaceuticals' quarterly Acquisitions came in at $300000.0 in Q4 2025, down 97.39% year-on-year from $11.5 million in Q4 2024, and down 90.0% quarter-over-quarter from $3.0 million in Q3 2025.

Regeneron Pharmaceuticals has reported Acquisitions for 3 years, with the latest figure at $300000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Acquisitions fell 97.39% year-over-year to $300000.0; the trailing twelve-month figure through Dec 2025 stood at $14.8 million (down 77.71% YoY), and the FY2025 full-year result was $3.3 million, down 80.0% from the prior year.
  • Acquisitions for Q4 2025 stood at $300000.0, down from $3.0 million in the prior quarter.
  • The five-year high for Acquisitions was $51.1 million in Q3 2023, with the low at $300000.0 in Q4 2025.
  • Average Acquisitions over 3 years is $13.9 million, with a median of $3.8 million recorded in 2023.
  • Year-over-year, Acquisitions jumped 202.63% in 2024 and plunged 97.39% in 2025.
  • Tracing REGN's Acquisitions over 3 years: stood at $3.8 million in 2023, then jumped by 202.63% to $11.5 million in 2024, then sank by 97.39% to $300000.0 in 2025.
  • The last three Acquisitions figures came in at $300000.0 (Q4 2025), $3.0 million (Q3 2025), and $11.5 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Revolution Medicines 31.20 Bn 31.20 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 300,000.00
Sep 30, 2025 3.00 Mn
Dec 31, 2024 11.50 Mn
Dec 31, 2023 3.80 Mn
Sep 30, 2023 51.10 Mn